Cardiff Oncology Stock Total Debt
| CRDF Stock | USD 3.78 1.34 54.92% |
Cardiff Oncology fundamentals help investors to digest information that contributes to Cardiff Oncology's financial success or failures. It also enables traders to predict the movement of Cardiff Stock. The fundamental analysis module provides a way to measure Cardiff Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cardiff Oncology stock.
The Cardiff Oncology's current Total Debt To Capitalization is estimated to increase to 0.01. Cardiff | Total Debt |
Cardiff Oncology Company Total Debt Analysis
Cardiff Oncology's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Cardiff Oncology Total Debt | 2.15 M |
Most of Cardiff Oncology's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cardiff Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cardiff Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Cardiff Oncology is extremely important. It helps to project a fair market value of Cardiff Stock properly, considering its historical fundamentals such as Total Debt. Since Cardiff Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cardiff Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cardiff Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
Cardiff Total Debt Historical Pattern
Today, most investors in Cardiff Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cardiff Oncology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cardiff Oncology total debt as a starting point in their analysis.
Cardiff Oncology Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Cardiff Net Debt
Net Debt |
|
Based on the latest financial disclosure, Cardiff Oncology has a Total Debt of 2.15 M. This is 99.92% lower than that of the Biotechnology sector and 99.34% lower than that of the Health Care industry. The total debt for all United States stocks is 99.96% higher than that of the company.
Cardiff Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cardiff Oncology's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cardiff Oncology could also be used in its relative valuation, which is a method of valuing Cardiff Oncology by comparing valuation metrics of similar companies.Cardiff Oncology is currently under evaluation in total debt category among its peers.
Cardiff Oncology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cardiff Oncology from analyzing Cardiff Oncology's financial statements. These drivers represent accounts that assess Cardiff Oncology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cardiff Oncology's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 7.4M | 7.4M | 375.5M | 61.0M | 70.2M | 66.7M | |
| Enterprise Value | (4.0M) | (1.1M) | 245.4M | 47.4M | 54.5M | 51.8M |
Cardiff Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cardiff Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cardiff Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Cardiff Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Cardiff Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cardiff Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cardiff Oncology's value.| Shares | Blair William & Co | 2024-09-30 | 247.1 K | Gsa Capital Partners Llp | 2024-09-30 | 186.7 K | Two Sigma Investments Llc | 2024-09-30 | 184.6 K | Bank Of New York Mellon Corp | 2024-09-30 | 171.1 K | Millennium Management Llc | 2024-09-30 | 152.7 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 143 K | Avestar Capital, Llc | 2024-09-30 | 140.5 K | Charles Schwab Investment Management Inc | 2024-09-30 | 121.3 K | Xtx Topco Ltd | 2024-09-30 | 120.4 K | Blackrock Inc | 2024-06-30 | 2.6 M | Vanguard Group Inc | 2024-09-30 | 2.2 M |
Cardiff Fundamentals
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (76.37) % | ||||
| Current Valuation | 133.21 M | ||||
| Shares Outstanding | 51.13 M | ||||
| Shares Owned By Insiders | 6.60 % | ||||
| Shares Owned By Institutions | 25.98 % | ||||
| Number Of Shares Shorted | 8.18 M | ||||
| Price To Earning | (0.48) X | ||||
| Price To Book | 3.83 X | ||||
| Price To Sales | 274.99 X | ||||
| Revenue | 488 K | ||||
| Gross Profit | (26.72 M) | ||||
| EBITDA | (45.01 M) | ||||
| Net Income | (41.44 M) | ||||
| Cash And Equivalents | 122.01 M | ||||
| Cash Per Share | 2.82 X | ||||
| Total Debt | 2.15 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 15.02 X | ||||
| Book Value Per Share | 1.01 X | ||||
| Cash Flow From Operations | (30.89 M) | ||||
| Short Ratio | 8.06 X | ||||
| Earnings Per Share | (0.95) X | ||||
| Target Price | 9.16 | ||||
| Number Of Employees | 31 | ||||
| Beta | 1.93 | ||||
| Market Capitalization | 189.19 M | ||||
| Total Asset | 81.64 M | ||||
| Retained Earnings | (339.54 M) | ||||
| Working Capital | 66.97 M | ||||
| Current Asset | 16.9 M | ||||
| Current Liabilities | 4.78 M | ||||
| Net Asset | 81.64 M |
About Cardiff Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cardiff Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiff Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardiff Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Cardiff Oncology is a strong investment it is important to analyze Cardiff Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiff Oncology's future performance. For an informed investment choice regarding Cardiff Stock, refer to the following important reports:Check out Cardiff Oncology Piotroski F Score and Cardiff Oncology Altman Z Score analysis. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.015 | Quarterly Revenue Growth 0.17 | Return On Assets (0.38) | Return On Equity (0.68) |
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.